Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received the approval and issuance from the National Medical Products Administration...
Shenzhentong Finance and Economics APP News, Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received the approval and issuance of the drug registration certificate for Phosphatidyl Acotinib Tablets from the National Medical Products Administration. Phosphatidyl Acotinib tablets were registered in Class 4 of chemical drugs, and once approved, were deemed to have passed consistency evaluation. The approval of this drug signifies that the product meets the relevant requirements for drug registration and will not have a significant impact on the company's recent performance.
The main ingredient of Phosphatidyl Acotinib tablets is phosphatidyl Acotinib, with indications for: 1. Myelofibrosis. Used in adult patients with intermediate or high-risk primary myelofibrosis (PMF), secondary myelofibrosis following polycythemia vera (PPV-MF), or secondary myelofibrosis following essential thrombocythemia (PET-MF) to treat disease-related splenomegaly or disease-related symptoms; 2. Graft-versus-host disease. Used to treat acute graft-versus-host disease (acute GVHD) or chronic graft-versus-host disease (chronic GVHD) in patients aged 12 and older when there is inadequate response to glucocorticoids or other systemic therapies.
